Epigenomic Profiling Advises Therapeutic Potential of Leukotriene Receptor Inhibitors for a Subset of Triple-Negative Breast Tumors

Epigenomic Profiling Advises Therapeutic Potential of Leukotriene Receptor Inhibitors for a Subset of Triple-Negative Breast Tumors

Triple-negative breast cancer (TNBC) is the most aggressive molecular subtype, with a poor survival rate compared to others subtypes. For a long time, chemotherapy was the only systemic treatment for TNBC, and the identification of actionable molecular targets might ultimately improve the prognosis...

Full description

Bibliographic Details
Main Authors: Alexey I. Kalinkin, Vladimir O. Sigin, Ekaterina B. Kuznetsova, Ekaterina O. Ignatova, Ilya I. Vinogradov, Maxim I. Vinogradov, Igor Y. Vinogradov, Dmitry V. Zaletaev, Marina V. Nemtsova, Sergey I. Kutsev, Alexander S. Tanas, Vladimir V. Strelnikov
Format: Article
Language:English
Published: MDPI AG 2023-12-01
Series:International Journal of Molecular Sciences
Subjects:
breast cancer
leukotriene receptors
DNA methylation
XmaI-RRBS
Online Access:https://www.mdpi.com/1422-0067/24/24/17343

Internet

https://www.mdpi.com/1422-0067/24/24/17343

Similar Items